More than CHF400 million in venture capital for Swiss start-ups
In recent years, the Swiss start-up scene has vastly improved in terms of quality and quantity, and as a result young entrepreneurs have become increasingly attractive to investors. Last year, young Swiss companies generated more than CHF400 million in venture capital. This figure compares very favourably with other European countries; for example, in Germany a relatively modest €690 million in venture capital was generated by start-ups in 2011. This is one of the main messages of the new startupticker’s Venture Capital Report 2012.
Of the 67 companies, which published information about their financing rounds, 29 are from the ICT, 10 from biotech and 12 from the medtech sector. The strength of ICT and medtech start-ups is also reflected in the invested sum. In 2012 CHF 188 million went to ICT companies and CHF118 million to medical technology start-ups followed by biotechnology (CHF101 million). Thus, start-up companies in the life sciences generated significantly more capital overall than IT companies.
The figures can be found in the first startupticker Venture Capital Report, based on continuous reporting by the startupticker.ch news portal on financing rounds by Swiss start-ups. The report contains a statistical analysis of the financing rounds, the 10 largest investments and a complete listing of all financing rounds. A PDF version of the report can be downloaded free.
Swiss start-up turns to the Nasdaq
Last year Auris Medical raised more than CHF47 million in venture capital for further growth. This was the largest round of financing in Switzerland in 2013. The company has two drugs in development: an injection for tinnitus and a drug for hearing loss in the inner ear. The tinnitus medication has already started the third and most expensive stage of development, the phase III trial. The Basel company, which has its headquarters in Zug, intends to raise the necessary capital on the Nasdaq: the IPO should bring Auris a total of $95 million in new money.